Scadden David — SEC Form 4 filings
SEC reporting owner CIK 1707715. 14 Form 4 filings on record with FilingPulse; latest filed 2026-06-23.
Transaction summary — filings shown
Covers all 14 filings on record, filed 2024-06-03 to 2026-06-23. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 6 legs across 6 filings — 2,400 shares, $98,224 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 28.
- Largest priced transaction: sale of 1,400 shares @ $40.00 ($56,000) in AGIOS PHARMACEUTICALS, INC., filed 2025-07-15.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | Director | 10 | — | 6 legs · 2,400 sh · $98,224 | 24 |
| Editas Medicine, Inc. (EDIT) | Director | 3 | — | — | 3 |
| Carisma Therapeutics Inc. (CARM) | Director | 1 | — | — | 1 |
Form 4 filings — Scadden David
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-23 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 2,816 @ $0 · Option exercise (M): 2,816 (derivative) @ $0 · Grant/award (A): 2,927 (derivative) @ $0 · Grant/award (A): 14,950 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Editas Medicine, Inc. (EDIT) | Grant/award (A): 51,700 (derivative) @ $0 | EDGAR |
| 2025-11-14 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 200 @ $18.09 · Sale (S): 200 @ $43.84 · Option exercise (M): 200 (derivative) @ $0 | EDGAR |
| 2025-10-10 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 200 @ $18.09 · Sale (S): 200 @ $41 · Option exercise (M): 200 (derivative) @ $0 | EDGAR |
| 2025-10-02 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 200 @ $18.09 · Sale (S): 200 @ $40 · Option exercise (M): 200 (derivative) @ $0 | EDGAR |
| 2025-08-29 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 200 @ $18.09 · Sale (S): 200 @ $40 · Option exercise (M): 200 (derivative) @ $0 | EDGAR |
| 2025-07-15 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 1,400 @ $18.09 · Sale (S): 1,400 @ $40 · Option exercise (M): 1,400 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 2,120 @ $0 · Grant/award (A): 2,816 (derivative) @ $0 · Grant/award (A): 15,768 (derivative) @ $0 · Option exercise (M): 2,120 (derivative) @ $0 | EDGAR |
| 2025-06-10 | 4 | Editas Medicine, Inc. (EDIT) | Grant/award (A): 37,500 (derivative) @ $0 | EDGAR |
| 2024-12-13 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 200 @ $18.09 · Sale (S): 200 @ $46.28 · Option exercise (M): 200 (derivative) @ $0 | EDGAR |
| 2024-07-01 | 4 | Carisma Therapeutics Inc. (CARM) | Grant/award (A): 38,700 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Grant/award (A): 2,120 (derivative) @ $0 · Grant/award (A): 11,774 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 3,388 @ $0 · Option exercise (M): 3,388 (derivative) @ $0 | EDGAR |
| 2024-06-03 | 4 | Editas Medicine, Inc. (EDIT) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1707715 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →